Table 2.
Serotype Prevalence in NP Specimens Obtained From All Study Subjects Enrolled in the Study (N = 6541)
| Serotype | Serotype, No. | Prevalence, % | 95% CI, %a |
| Vaccine types (VTs) | |||
| All VTs | 56 | 0.9 | .6–1.1 |
| 19F | 35 | 0.5 | .3–.8 |
| 9V | 7 | 0.1 | .0–.2 |
| 4 | 5 | 0.1 | .0–.2 |
| 14 | 4 | 0.1 | .0–.1 |
| 6B | 4 | 0.1 | .0–.2 |
| 18C | 1 | 0.02 | .0–.04 |
| All NVTs | 2357 | 36.0 | 34.9–37.3 |
| Vaccine-associated types (VATs) | |||
| All VATs | 676 | 10.3 | 9.5–11.1 |
| 6Cb | 228 | 3.5 | 3.1–4.0 |
| 19A | 208 | 3.2 | 2.5–3.8 |
| 23B | 137 | 2.1 | 1.6–2.6 |
| 23A | 89 | 1.4 | 1.0–1.8 |
| 9N | 9 | 0.1 | .1–.2 |
| 6A | 5 | 0.1 | .0–.2 |
| NVTs excluding VATs | |||
| 35B | 137 | 2.1 | 1.8–2.5 |
| 22F | 134 | 2.1 | 1.7–2.4 |
| NT | 133 | 2.0 | 1.7–2.4 |
| 15A | 132 | 2.0 | 1.7–2.4 |
| 17F | 96 | 1.5 | 1.0–1.9 |
| 11A | 92 | 1.4 | 1.0–1.9 |
| 34 | 89 | 1.4 | 1.0–1.7 |
| 21 | 88 | 1.3 | .9–1.8 |
| 10A | 85 | 1.3 | .9–1.7 |
| 16F | 83 | 1.3 | .1–1.7 |
| 15B | 74 | 1.1 | .9–1.4 |
| 3 | 73 | 1.1 | .9–1.4 |
| 33F | 60 | 0.92 | .6–1.2 |
| 7C | 60 | 0.92 | .6–1.2 |
| 35F | 58 | 0.89 | .6–1.2 |
| 35A | 55 | 0.84 | .6–1.2 |
| 15C | 50 | 0.76 | .5–1.0 |
| 31 | 50 | 0.76 | .5–1.0 |
| 38 | 32 | 0.49 | .3–.7 |
| 12F | 25 | 0.38 | .2–.6 |
| 10F | 25 | 0.38 | .2–.6 |
| 7F | 13 | 0.20 | .1–.3 |
| 8 | 11 | 0.17 | .0–.3 |
| 37 | 10 | 0.15 | .0–.3 |
| 1 | 8 | 0.12 | .0–.2 |
| 5 | 2 | 0.03 | .0–.1 |
| 10C | 1 | 0.02 | .0–.1 |
| 20 | 1 | 0.02 | .0–.1 |
| 22A | 1 | 0.02 | .0–.1 |
| 27 | 1 | 0.02 | .0–.1 |
| 28 | 1 | 0.02 | .0–.1 |
| 33A | 1 | 0.02 | .0–.1 |
a
If 95% confidence interval (CI) crossed 0 (owing to extrabinomial variation common with identity link models), .0 is listed as the low end of interval.
b
This group includes 3 isolates that were not available for retesting and were assumed to be 6C.